🌎 30+ NEW AI-picked share strategies for exciting international marketsUnlock Global AI Picks

Frontier IP: The Vaccine Group gets £1mln of funding support from Defra

Published 05/09/2024, 09:17
Updated 05/09/2024, 09:40
© Reuters.  Frontier IP: The Vaccine Group gets £1mln of funding support from Defra

© Reuters. Frontier IP: The Vaccine Group gets £1mln of funding support from Defra

IPO
-0.39%

Proactive Investors - Frontier IP Group (LON:IPO) portfolio company The Vaccine Group (TVG) has been awarded more than £1 million in funding by the UK Government to develop a vaccine for Streptococcus suis.

This bacterial infection is seen as a significant risk to pig farming productivity, and, significantly, can also be transmitted to humans, causing diseases such as meningitis and septicaemia.

TVG’s project aims to create a vaccine that offers protection against multiple strains of Streptococcus suis, a disease that affects an estimated 60% of pig farms across Europe.

Currently, no vaccine exists that protects against different strains of the disease, and farmers must rely on antibiotics to treat infections.

The development of an effective vaccine would reduce the need for antibiotics, aligning with government goals to cut antibiotic use in livestock by 50% by 2030.

The grant funding comes from the Department for Environment, Food & Rural Affairs (Defra) and is delivered through Innovate UK.

Meanwhile, the project itself is a collaboration between TVG, the University of Plymouth, and the University of Cambridge.

"We are delighted that Defra is supporting this project,” said Matthew White, Frontier IP’s chief commercialisation officer.

“Streptococcus suis can cause significant economic harm to pig farmers and is potentially fatal to humans. With governments globally looking to curb antibiotic use, developing effective vaccines is crucial."

TVG chief executive Dr Jeremy Salt, meanwhile, added: “For pig farmers across the UK, Streptococcus suis is a major cause for concern and can lead to significant losses - both in terms of animals and financially.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

"Our goal in developing an effective vaccine is to stop the bacterial infection from developing in pigs and humans in the first place.

“By doing so, we can protect the farmers, their animals, and their livelihoods."

Frontier IP holds a 17% stake in TVG.

Read more on Proactive Investors UK

Disclaimer

Is IPO truely undervalued?

With IPO making headlines, investors are asking: Is it truly valued fairly? InvestingPro's advanced AI algorithms have analyzed IPO alongside thousands of other stocks to uncover hidden gems with massive upside. And guess what? IPO wasn't at the top of the list.

Unlock ProPicks AI

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.